RT info:eu-repo/semantics/article
T1 Safety of Beta‐lactoglobulin as a Novel food pursuant to Regulation (EU) 2015/2283
A1 Turck, Dominique
A1 Bohn, Torsten
A1 Castenmiller, Jacqueline
A1 De Henauw, Stefaan
A1 Hirsch‐Ernst, Karen Ildico
A1 Maciuk, Alexandre
A1 Mangelsdorf, Inge
A1 McArdle, Harry J
A1 Naska, Androniki
A1 Peláez, Carmen
A1 Pentieva, Kristina
A1 Siani, Alfonso
A1 Thies, Frank
A1 Tsabouri, Sophia
A1 Vinceti, Marco
A1 Cubadda, Francesco
A1 Frenzel, Thomas
A1 Heinonen, Marina
A1 Marchelli, Rosangela
A1 Neuhäuser‐Berthold, Monika
A1 Poulsen, Morten
A1 Prieto Maradona, Miguel
A1 Schlatter, Josef Rudolf
A1 van Loveren, Henk
A1 Fernández Dumont, Antonio
A1 Noriega Fernández, Estefanía
A1 Knutsen, Helle Katrine
A2 Nutricion y Bromatologia
K1 Tecnología de los alimentos
K1 Beta-lactoglobulin
K1 Novel food
K1 Whey protein isolate
K1 3206 Ciencias de la Nutrición
K1 3309 Tecnología de Los Alimentos
AB [EN] Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on beta-lactoglobulin (BLG) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF (≥ 90% w/w dry matter protein) consists of BLG as primary component (≥ 90% of total protein), which is equivalent to BLG present in bovine milk and whey protein isolate (WPI). The NF is produced from bovine whey by crystallisation under acidic or neutral conditions. The NF is proposed to be used as a food ingredient in isotonic and sport drinks, whey powder and milk-based drinks and similar products, and in food for special medical purposes as defined in Regulation (EU) No 609/2013. The target population is the general population. The highest daily intake of the NF was estimated for children of 3 to < 10 years of age as 667 mg/kg body weight (bw) per day. The NF presents proximate composition and content of essential amino acids similar to those in WPI. The Panel notes that the highest mean and highest 95th percentile daily protein intakes from the NF are below the protein population reference intakes for all population groups. Although a tolerable upper intake level has not been derived for protein, the protein intake from the NF may nevertheless further contribute to an already high dietary protein intake in Europe. The exposure to the reported minerals does not raise concerns. The Panel considers that the consumption of the NF is not nutritionally disadvantageous. No genotoxic concerns were identified from the standard in vitro test battery. No adverse effects were observed in the subchronic toxicity study, up to the highest dose tested, i.e. 1,000 mg NF/kg bw per day. The Panel concludes that the NF is safe under the proposed conditions of use.
PB Wiley Open Access
SN 1831-4732
LK https://hdl.handle.net/10612/20485
UL https://hdl.handle.net/10612/20485
NO Turck, D., Bohn, T., Castenmiller, J., De Henauw, S., Hirsch-Ernst, K. I., Maciuk, A., Mangelsdorf, I., McArdle, H. J., Naska, A., Peláez, C., Pentieva, K., Siani, A., Thies, F., Tsabouri, S., Vinceti, M., Cubadda, F., Frenzel, T., Heinonen, M., Marchelli, R., et al. (2022). Safety of Beta-lactoglobulin as a Novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 20(4), Article e7204. https://doi.org/10.2903/J.EFSA.2022.7204
DS BULERIA. Repositorio Institucional de la Universidad de León
RD Jul 6, 2024